can you see news from insiders or less accessible and understand if there could be a spike in the price of Eyenovia?

Here is some news about Eyenovia:

1. Successful Launch of APP13007: Eyenovia and Formosa Pharma successfully launched APP13007, the first FDA-approved ophthalmic drug using clobetasol propionate. This launch has led to a significant surge in Eyenovia's stock price by 14.94%.
2. Taiwan Export License Approval: Eyenovia's strategic partner, Formosa Pharmaceuticals, was granted a Taiwan export license for clobetasol propionate ophthalmic suspension 0.05% to allow for shipment of commercial product to the U.S. This development is a milestone for the company's U.S. launch of clobetasol, planned for late September 2024.
3. Appointment of New CFO: Eyenovia announced the appointment of Andrew Jones as Chief Financial Officer, bringing extensive finance and accounting leadership experience to the company. This appointment is part of the company's strategic planning as it approaches critical data readouts and commercial launches.
4. Insider Transactions: Eyenovia's CEO, Michael M. Rowe, purchased 50,000 shares of the company's stock at an average cost of $0.57 per share, demonstrating confidence in the company's future performance.
5. Financial Projections and Analyst Ratings: Analysts have increased their EPS estimates for Eyenovia, indicating improved financial performance. Additionally, HC Wainwright reiterated a "buy" rating and set a price target of $12.00 per share, suggesting potential for price appreciation.

In conclusion, the successful launch of APP13007, the Taiwan export license approval, the appointment of a new CFO, insider transactions, and positive financial projections by analysts, all point to a company that is moving forward in a positive direction. The planned U.S. launch of clobetasol propionate ophthalmic suspension could lead to a significant spike in the price of Eyenovia's stock as the market responds to this new product opportunity.